Balapiravir_product_DataBase

Bioactivity

Balapiravir (Ro 4588161; R1626) is an orally active prodrug of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity[1][2][3].

In Vivo

After oral dosing of the CD-1 mice with 28.1 mg/kg of balapiravir (Ro 4588161; R1626), R1479 reaches a Cmax and a minimum concentration in plasma (Cmin) of 24.38 μM and 6.34 μM, respectively, at 2 h and 24 h postdosing[3].

Name

Balapiravir

CAS

690270-29-2

Formula

C21H30N6O8

Molar Mass

494.50

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Nguyen NM, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013 May 1;207(9):1442-1450. [2]. Nelson DR, et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.Ann Hepatol. 2012 Jan-Feb;11(1):15-31. [3]. Yen-Liang Chen, et al. Activation of Peripheral Blood Mononuclear Cells by Dengue Virus Infection Depotentiates Balapiravir. J Virol. 2014 Feb;88(3):1740-7.

PeptideDB

Balapiravir

CAS: 690270-29-2 F: C21H30N6O8 W: 494.50